Impact of Protein Quantity Within the USDA Healthy Style Eating Pattern on Sleep

December 19, 2019 updated by: Wayne Campbell, Purdue University

Effects of Higher Consumption of Protein-rich Animal Foods With the USDA Healthy U.S.-Style Eating Pattern on Sleep Quality and Cardio-metabolic Health in Overweight/Obese Adults During Diet-induced Weight Loss

This evaluates the affect of protein quantity on indices of sleep. Half the participants will be prescribed protein in the amount consistent with the USDA healthy style eating pattern, while the other half will be prescribed a diet containing 12.5 oz eq of protein.

Study Overview

Status

Completed

Conditions

Detailed Description

According to the National Sleep Foundation, 13% of U.S. adults were reported to sleep 6 hours or less per weeknight in 2001. Eight years later, the number increased to 20%. Also, the proportion of people experiencing a sleep problem (e.g. difficulties in initiating or maintaining sleep) several nights per week has increased dramatically (from 51% to 64% in 2001 to 2009). Getting enough and good quality sleep is essential to health. Indices of sleep, including duration, quality, and patterning are related to obesity, type 2 diabetes, cardiovascular disease, hypertension, worsen lipid-lipoprotein status, and premature death. All of these morbidities and mortality are also impacted by diet .

The 2015 Dietary Guidelines Advisory Committee recognized "an insufficient body of evidence" in the "emerging area" of "associations between sleep patterns, dietary intakes, and obesity risk" and that "a paucity of research exists on the potential impact of diet on sleep-related outcomes". Currently the majority of research has assessed the influence of sleep on energy balance or dietary choices. The reversed relation, how diet influence sleep, received much less attention. In general, diet-induced weight loss is considered to improve sleep quality and increase sleep duration. However, emerging research brings into question the impact of the macronutrient distribution during dietary energy restriction (ER) on indices of sleep. Dietary protein, due to its ability to provide tryptophan and tyrosine (precursors of neurotransmitters melatonin and dopamine), may influence sleep. Despite the fact that both diet and sleep predict obesity and chronic diseases, limited research exists on the effects of dietary energy and macronutrients, especially high-quality protein intake, on indices of sleep.

The primary aim is to assess the effects of the USDA Healthy U.S.-Style Eating Pattern with higher amounts of animal-based protein-rich foods (lean meats and eggs) on health outcomes including sleep and blood pressure.

This is a 16-week randomized, parallel, placebo-controlled, single-blind study. During baseline, participant's diet, general health, and sleep quality will be assessed. Participants will then be randomized and assigned to either the normal protein or high protein (5 vs. 12.5 oz-eq of protein foods daily) for the 12-week weight loss intervention with the energy-restriction (750 kcal/day dietary energy deficits).

Study Type

Interventional

Enrollment (Actual)

71

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Indiana
      • West Lafayette, Indiana, United States, 47907
        • Purdue University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 69 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male or female; age 35-65 y; BMI 25-39 kg∙m-2; weight stable (± 3 kg) 3 months pre-study; no acute illness; not diabetic; not pregnant or lactating; not currently (or within 3 months pre-study) following an exercise or weight loss program; non-smoking; not lactose intolerant; natural waist circumference ≥ 102 cm for men and ≥ 88 cm for women; fasting glucose < 110 mg/dL, systolic and diastolic blood pressures < 140/90 mmHg; serum total cholesterol < 260 mg/dL; LDL-cholesterol < 160 mg/dL; triacylglycerol < 400 mg/dL; PSQI score ≥ 5; and clinically normal serum albumin and pre-albumin concentrations. In addition, subjects who have been diagnosed by their doctor with moderate to severe sleep apnea or insomnia will be excluded during screening.

Exclusion Criteria:

  • Diabetic, smoker

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Normal Protein with weight loss

weight loss subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age

Meal Pattern USDA Healthy U.S.-Style Eating Pattern with ~5 oz eq of protein foods for 12 wk

Following a two week baseline assessment period, subjects will consume a diet with normal protein diet while undergoing weight loss for 12 wk.
Experimental: High protein and weight loss

weight loss subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age

Meal Pattern USDA Healthy U.S.-Style Eating Pattern with ~12.5 oz eq of protein foods for 12 wk

Following a two week baseline assessment period, subjects will consume a diet with high protein diet while undergoing weight loss for 12 wk.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Disordered sleep
Time Frame: 12 weeks
Will be assessed using the Actiwatch. Each participant will wear the Actiwatch on their wrist for 7 days as directed by the study coordinator. Outcome measurements include: real sleep time, latency, efficiency, wake time, and wake bouts.
12 weeks
Physiologic sleep onset
Time Frame: 12 weeks
All participants will be given saliva collection tubes and instruction on how to collect will be in the kit given. This for our lab to measure saliva melatonin concentrations during the 7 days they are wearing the Actiwatch. Subjects will collect saliva hourly from 5 hours before to 2 hours before usual sleep time, then every 30 minutes until 1 hour before usual sleep time. Subjects will be given collections tubes and detailed collection instructions prior to the testing period. After sample collection, you will place the saliva filled tubes in there protective container and place the container in your refrigerator. You will keep collected samples until testing for that period is complete and you return them to the study coordinator (≤ 7 days).
12 weeks
Subjective sleep quality
Time Frame: 12 weeks
Will be assessed using the Pittsburgh Sleep Quality Index questionnaire on a single testing day. The PSQI questionnaire is a clinical sleep behavior questionnaire validated for use in patients with insomnia, cancer, Parkinson's disease, and the general population. It is designed to assess indices of sleep during the preceding one-month interval and contains 19 questions using Likert scales from 0-3. All questions are categorized into seven sub-parameters (duration of sleep, sleep disturbance, sleep latency, day dysfunction due to sleepiness, sleep efficiency, subjective sleep quality, and use of sleeping medication). Each of these seven parameters is scored between 0 and 3 arbitrary units (au), which generates a summed total score of 0 to 21 au. This total score (GSS) of >5 au indicates poor sleep condition. Thus, a lower GSS score indicates better sleep condition. The PSQI also has questions that generate routine sleep duration in hours.
12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fasting state blood analyses
Time Frame: 12 weeks
clinical blood chemistries
12 weeks
Blood pressure
Time Frame: 12 weeks
24 h and clinical blood pressures
12 weeks
Body composition
Time Frame: 12 weeks
BodPod
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2017

Primary Completion (Actual)

October 30, 2019

Study Completion (Actual)

October 30, 2019

Study Registration Dates

First Submitted

May 31, 2017

First Submitted That Met QC Criteria

May 31, 2017

First Posted (Actual)

June 2, 2017

Study Record Updates

Last Update Posted (Actual)

December 20, 2019

Last Update Submitted That Met QC Criteria

December 19, 2019

Last Verified

December 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • 1701018623

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sleep

Clinical Trials on Normal protein

Subscribe